General anaesthesia for the patient with a history of anaesthesia-related anaphylaxis is challenging. Precautions against anaphylaxis and the use of skin test negative drugs can reduce but not eliminate the risk. In the majority of such cases, subsequent anaesthesia is uneventful. However, the absence of a clearly identified triggering agent increases the difficulties facing the anaesthetist. We present a case of anaphylaxis to cisatracurium following a negative skin test.
Anaphylaxis is a potentially life-threatening event with an estimated incidence in relation to anaesthesia of between 1:6,000-1:20,000 1,2 anaesthetics. As causative agents, the neuromuscular blocking drugs (NMBDs) have consistently been shown to have the highest risk of anaphylaxis, causing up to 75% of all cases during anaesthesia 3 . It has been suggested that the introduction of lower-risk agents such as cisatracurium, and the subsequent reduction in the use of higher risk agents such as suxamethonium and alcuronium, has led to an overall reduction in anaphylaxis rates over recent years 4 . While it is important to identify the agent responsible for an anaphylactic reaction in order to avoid further reactions in subsequent anaesthetics, this can be problematic in a situation where multiple drugs are given over a short period. Currently, the best available method for identifying the triggering agent is intradermal testing 5 , although such testing is not infallible. Here we present a case of a patient with a previous anaphylaxis, who had a subsequent anaphylactic reaction to cisatracurium. This occurred despite a negative skin test, prophylactic premedication with H1 and H2 antagonists and corticosteroids, and the use of an intravenous test dose.
CASE HISTORY
A 76 kg, 47-year-old man presented for excision of a right parietal meningioma, detected during investigation for seizures. He was a smoker and had a history of hiatus hernia and gastro-oesophageal reflux, but no other significant medical history. He had had two previous uneventful general anaesthetics using midazolam, propofol and fentanyl, but without muscle relaxation. On presentation for surgery his only medication was phenytoin, and he had no known allergies. He worked in a café where he wore latex gloves on a daily basis.
Invasive blood pressure monitoring was established and a pre-induction dose of midazolam was administered. General anaesthesia was induced with propofol and remifentanil, and muscle relaxation was provided by suxamethonium 100 mg followed five minutes later by rocuronium 50 mg. Within minutes the patient developed severe bronchospasm, became bradycardic, and suffered a cardiac arrest with pulseless electrical activity. Cardiopulmonary resuscitation was commenced immediately. He received intravenous fluids and a total of 7 mg of adrenaline before central venous access was obtained and highdose adrenaline and noradrenaline infusions were commenced. An episode of ventricular fibrillation was treated with DC shock and he then reverted to pulseless electrical activity. After 35 minutes of resuscitation he developed pulseless supraventricular tachycardia (rate 250 beats/min), received a further DC shock, and reverted to sinus rhythm with a good cardiac output and blood pressure. Surgery was deferred and he was transferred to ICU on decreasing doses of inotropic agents. He was extubated later that evening and subsequently made a full recovery with no persisting neurological deficit. Mast cell tryptase levels taken at 25 minutes and three hours post arrest were both >200 µg/l (normal <15), consistent with a diagnosis of anaphylaxis.
The patient was referred to the Allergy Unit and testing was conducted six weeks later. A RAST test for latex was mildly positive (0.45 kUA/l, normal <0.35). Intradermal testing was performed to all agents used, as well as alternative agents, according to the General Anaesthetic Challenge Protocol utilized by the Unit (Table 1) .
boluses (222 mg). At this point it was decided that more profound relaxation was desirable to prevent patient movement whilst secured with Mayfield pins. Cisatracurium was chosen due to the clear negative skin test. A test dose of 1 mg was given intravenously. Soon after, the patient became hypotensive (BP 70/40 mmHg), with high inspiratory pressures (44-48 cmH 2 O), reduced oxygen saturation (90%), an obstructive pattern on capnography, and generalized erythema. He was treated with adrenaline, increments of salbutamol IV to 300 µg, nebulized salbutamol and ipratropium bromide, and an aminophylline infusion. Bronchospasm was present for several hours before gradual resolution of symptoms. During this time he remained in the operating theatre due to the lack of availability of an ICU bed, and to maintain a latex-free environment. Ten hours after induction his abnormal signs had resolved, with normal inspiratory pressures and arterial PCO 2 . At this point it was decided to proceed with surgery using an anaesthetic of propofol and remifentanil by infusion and vecuronium for muscle relaxation. The surgical procedure was uneventful. He was extubated at the end of the case without incident, made a full recovery, and was discharged home several days later. After consultation with the Allergy Unit it was decided not to proceed with repeat skin-testing due to the clear temporal relation between drug administration and reaction during the second anaesthetic.
DISCUSSION
Life-threatening allergic reactions to anaesthetic drugs occur approximately once in every 6,000-20,000 anaesthetics 4 . When a reaction occurs, available evidence suggests that skin testing with appropriate concentrations of drugs is useful in establishing the responsible agent and in identifying those drugs that may be used with some confidence in the future 5,6 . This is particularly important when a muscle relaxant is suspected as the causative agent as cross-reactivity between relaxants occurs in up to 70% of patients 6 . The sensitivity of skin tests for muscle relaxants has been shown to be 94-97% 7 and it has been suggested that if a causative agent is identified, then drugs with a negative skin test are safe to use 6 . Whilst reactions to skin test negative drugs are very uncommon, a few cases have been previously reported. In 1999, Fisher and colleagues 5 reported only three patients out of 1346 in 25 years of skin testing, in which a test-negative drug (suxamethonium, alcuronium and vecuronium respectively) was deemed to be responsible for a subsequent reaction. There are two postulated explanations for this: either development The Allergy Unit concluded that this was a case of definite anaphylaxis, but of unknown aetiology, and devised a plan for subsequent surgery. It was decided that atracurium and all muscle relaxants previously used should be avoided. Propofol, midazolam and fentanyl were deemed safe to use in view of the negative skin tests and their use in previous uneventful anaesthetics.
Eight weeks after the initial event, the patient returned for surgery. In the interim he had experienced an increase in seizure activity, treated with phenytoin and dexamethasone. On the advice of the Allergy unit he was treated in a latex-free environment and premedicated with promethazine (25 mg IV), hydrocortisone (250 mg IV), sodium citrate (30 ml orally) and ranitidine (50 mg IV). A preinduction dose of midazolam caused a small area of erythema around the IV site, but no other clinical effect. General anaesthesia was induced with propofol and fentanyl, and tracheal intubation was facilitated by vecuronium (8 mg). Anaesthesia was maintained with isoflurane in oxygen and nitrous oxide. After 65 minutes (and prior to skin incision) the patient was stable (blood pressure 135/70 mmHg, peak airway pressure 22 cmH 2 O, SpO 2 100%), but his train-of-four count remained between 2 and 3, despite an infusion of vecuronium (12 mg/h) and intermittent vecuronium of a new sensitivity to that agent, or a false negative result on skin testing. Evidence suggests that new sensitivities can develop, but this is usually considered to take time. Bouaziz and Laxenaire 6 recommend that as cross-sensitivity is common and allergy profiles may change over time, patients who have had a previous anaphylaxis should be re-tested prior to surgery if two to three years have elapsed. In Fisher et al's series of reports, follow-up anaesthesia and subsequent reactions occurred at 2 months, 5 months and 4 years following skin testing respectively. All three patients reported had a triggering agent positively identified on skin testing, and were thought to have had false negative results for the drugs to which they subsequently reacted. In our case, no initial causative agent was identified at skin testing, perhaps suggesting a false negative result. Although a positive result was recorded for atracurium, this was not one of the drugs given during the initial anaesthetic.
Anaphylactic reactions to cisatracurium are unusual. Cisatracurium is a relatively new nondepolarizing muscle relaxant of the benzylisoquinolinium family, and is one of the ten stereoisomers of atracurium. Its purported advantages include having a reduced risk of direct histamine release 8 and allergic reaction 9 . The true incidence of anaphylaxis to cisatracurium is difficult to estimate due to its relatively recent introduction and small percentage of market share. A French two-year study 10 attempted to quantify the risk of reaction of the different NMBDs relative to their usage, and concluded by classifying cisatracurium as a low risk agent. Cisatracurium was responsible for only 0.6% of anaphylactic reactions despite a 4.1% market share. Krombach and colleagues' series of case reports cautiously estimate an incidence of anaphylaxis to cisatracurium as 1 in 10,000 exposures 11 . However, there have recently been at least 16 reports of anaphylactic/anaphylactoid reactions to cisatracurium [11] [12] [13] [14] [15] [16] [17] . All of these reactions appear to have occurred on the patient's first exposure to cisatracurium, although two patients had previously received atracurium. This phenomenon is highly suggestive of cross-reactivity due to the quaternary ammonium compound which is also present in other drugs (including other muscle relaxants), food, soaps and cosmetics. Interestingly, in two of the reported cases, a pre-curarizing dose only was used, as low as 12 mg/kg 11 . All patients with a suspected anaphylactic reaction to cisatracurium had a positive result on follow-up allergy testing.
To our knowledge, this is the first reported case of a reaction to cisatracurium following a negative skin test.
The difference in skin test results for atracurium and cisatracurium are of interest. It has been suggested that as atracurium and cisatracurium are stereoisomers, their immune profiles should be the same, and that allergy to one isomer equates to allergy to the other 15, 18 . However, a population of "superresponders" has been described 18 , in whom direct histamine release from atracurium leads to positive skin reactions, whilst testing to cisatracurium is negative. It has been recommended that it is necessary to conduct skin testing on only one of the drugs to test for allergy to both and that cisatracurium is the preferred drug for testing because of atracurium's cutaneous histamine releasing properties 16 . In our case, cisatracurium was chosen due to decreased effectiveness of vecuronium (most likely due to increased metabolism and reduced sensitivity secondary to phenytoin administration 19 ), a desire to avoid relaxants used in the previous anaesthetic and, importantly, a clear negative skin test. The subsequent response provides further support to the argument that the two agents have the same allergic potential, and suggest that cisatracurium should be avoided in the setting of a positive response to atracurium.
Whilst it is generally accepted that test-negative drugs are safe to use when a causative agent is identified, how should we approach subsequent anaesthesia when no such trigger is identified? Although there are many reports of negative skin tests, there are few reports of problems during subsequent anaesthetics. Whilst test-negative drugs are likely to be safe, we cannot be as confident using such drugs in these situations. A negative test clearly does not eliminate the risk of anaphylaxis in subsequent anaesthetics. If no causative agent can be identified, all NMBDs should be avoided whenever possible. However, in those situations when muscle relaxation is necessary, how can the risk of adverse reactions be minimized? The agent suspected of causing the initial reaction should be avoided, as should high risk agents, such as suxamethonium. Low risk agents such as pancuronium and cisatracurium are considered safer options, but the anaesthetist should be alert to the risk of reactions and be prepared to treat promptly. Other strategies have been suggested, but so far without any conclusive evidence to support their use. These include prophylactic premedication, desensitization, and test dose use. A combination of H1 and H2 receptor antagonists have been shown to reduce the frequency of allergic reactions to colloids 20 , whilst prednisolone and phenhydramine with or without ephedrine have been reported to attenuate the response to radio-contrast media 21 . H1 and H2 b. a. FRaseR, J. a. smaRT antagonists have also been shown to reduce the clinical effects of direct histamine release during induction of general anaesthesia in non-allergic subjects 22 . Programs of desensitization appear to have a role in antibiotic allergy. Unfortunately, none of these strategies has been shown to be useful for NMBD allergy. It has even been suggested that prophylactic agents may blunt the early signs of anaphylaxis, leaving a full-blown reaction as the first presentation, and should therefore be reserved for the treatment of an established reaction 23 . In our case, several of these strategies were implemented, and may have contributed to reducing the severity of the reaction during the second anaesthetic. This case highlights the importance of a good anaesthetic plan and a high index of suspicion when dealing with a patient with a history of anaesthesia-related anaphylaxis.
